Daniel Taussky1,2, Denis Souliéres3,4, Laurent Azoulay5,6, Hui Yin5,6, Houda Bahig3,7, Jean-Paul Bahary3,7, Guila Delouya3,7. 1. Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal - Hôpital Notre-Dame, 1560 Sherbrooke St. E., Montreal, QC, H2L 4M1, Canada. daniel.taussky.chum@ssss.gouv.qc.ca. 2. CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada. daniel.taussky.chum@ssss.gouv.qc.ca. 3. Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal - Hôpital Notre-Dame, 1560 Sherbrooke St. E., Montreal, QC, H2L 4M1, Canada. 4. Department of Medical Oncology, Centre Hospitalier de l'Université de Montréal Hôpital Notre-Dame, Montreal, QC, Canada. 5. Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada. 6. Department of Oncology, McGill University, Montreal, QC, Canada. 7. CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Abstract
BACKGROUND: It has been shown that neutrophil count or an elevated neutrophil-to-lymphocyte ratio (NLR) as well as testosterone levels are separately associated with increased mortality in patients with localized prostate cancer. OBJECTIVE: We tested a combination of testosterone levels and white blood cell (WBC) counts to predict overall survival (OS) in a prospective cohort of patients treated with radiotherapy for localized prostate cancer. PATIENTS AND METHODS: The 381 patients included in this study were prospectively enrolled in phase 2 or 3 studies. Multivariate Cox proportional hazards models were used to analyze the influence of WBC count and testosterone level on biochemical recurrence and OS. Cutoff levels of ≤10.4 nmol/L (300 ng/dL) for testosterone and a median value of 6.2 (×109/L) for WBC count were used. RESULTS: The median follow-up for biochemical recurrence and OS were 72 and 78 months, respectively. A WBC count of ≥6.2 alone was not associated with OS (hazard ratio [HR] 0.66; 95% confidence interval [CI] 0.30-1.46). When combined with a testosterone level of >10.3 nmol/L, a WBC count of ≥6.2 was associated with increased mortality (HR 2.96; 95% CI 1.45-6.06) when compared with a WBC count of <6.2 (p-interaction = 0.01). The HR for biochemical recurrence for patients with a testosterone level >10.3 nmol/L combined with a lymphocyte level above or equal to the median was nearly identical to the HR of a testosterone level >10.3 nmol/L with a WBC above or equal to the median. There was no association between testosterone level and the NLR. CONCLUSIONS: A high WBC and lymphocyte count combined with normal testosterone levels increases the overall mortality of patients treated with radiotherapy for localized prostate cancer within the first 6-7 years post-treatment. Validation in larger cohorts is necessary.
BACKGROUND: It has been shown that neutrophil count or an elevated neutrophil-to-lymphocyte ratio (NLR) as well as testosterone levels are separately associated with increased mortality in patients with localized prostate cancer. OBJECTIVE: We tested a combination of testosterone levels and white blood cell (WBC) counts to predict overall survival (OS) in a prospective cohort of patients treated with radiotherapy for localized prostate cancer. PATIENTS AND METHODS: The 381 patients included in this study were prospectively enrolled in phase 2 or 3 studies. Multivariate Cox proportional hazards models were used to analyze the influence of WBC count and testosterone level on biochemical recurrence and OS. Cutoff levels of ≤10.4 nmol/L (300 ng/dL) for testosterone and a median value of 6.2 (×109/L) for WBC count were used. RESULTS: The median follow-up for biochemical recurrence and OS were 72 and 78 months, respectively. A WBC count of ≥6.2 alone was not associated with OS (hazard ratio [HR] 0.66; 95% confidence interval [CI] 0.30-1.46). When combined with a testosterone level of >10.3 nmol/L, a WBC count of ≥6.2 was associated with increased mortality (HR 2.96; 95% CI 1.45-6.06) when compared with a WBC count of <6.2 (p-interaction = 0.01). The HR for biochemical recurrence for patients with a testosterone level >10.3 nmol/L combined with a lymphocyte level above or equal to the median was nearly identical to the HR of a testosterone level >10.3 nmol/L with a WBC above or equal to the median. There was no association between testosterone level and the NLR. CONCLUSIONS: A high WBC and lymphocyte count combined with normal testosterone levels increases the overall mortality of patients treated with radiotherapy for localized prostate cancer within the first 6-7 years post-treatment. Validation in larger cohorts is necessary.
Authors: Frederick C W Wu; Abdelouahid Tajar; Jennifer M Beynon; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Steven Boonen; Dirk Vanderschueren; Fernand Labrie; Ilpo T Huhtaniemi Journal: N Engl J Med Date: 2010-06-16 Impact factor: 91.245
Authors: Bu B Yeap; Helman Alfonso; S A Paul Chubb; David J Handelsman; Graeme J Hankey; Osvaldo P Almeida; Jonathan Golledge; Paul E Norman; Leon Flicker Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Jochen Walz; Andrea Gallina; Paul Perrotte; Claudio Jeldres; Quoc-Dien Trinh; Georg C Hutterer; Miriam Traumann; Alvaro Ramirez; Shahrokh F Shariat; Michael McCormack; Jean-Paul Perreault; Francois Bénard; Luc Valiquette; Fred Saad; Pierre I Karakiewicz Journal: BJU Int Date: 2007-12 Impact factor: 5.588
Authors: Jochen Walz; Andrea Gallina; Fred Saad; Francesco Montorsi; Paul Perrotte; Shahrokh F Shariat; Claudio Jeldres; Markus Graefen; Francois Bénard; Michael McCormack; Luc Valiquette; Pierre I Karakiewicz Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: Matthew Kent; David F Penson; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Janet L Stanford; Antoinette M Stroup; Behfar Ehdaie; Peter T Scardino; Andrew J Vickers Journal: BMC Med Date: 2016-02-09 Impact factor: 8.775
Authors: Afroditi Nanou; Linda Mol; Frank A W Coumans; Miriam Koopman; Cornelis J A Punt; Leon W M M Terstappen Journal: Cells Date: 2020-12-15 Impact factor: 6.600
Authors: Luke A Robles; Sean Harrison; Vanessa Y Tan; Rhona Beynon; Alexandra McAleenan; Julian Pt Higgins; Richard M Martin; Sarah J Lewis Journal: Cancer Causes Control Date: 2022-06-26 Impact factor: 2.532